SCHEMBL13430279

SCHEMBL13430279

CN(C)CCCOc1ccc2c(NCCC3CN=C(NC(=O)Nc4ccccc4)S3)ccnc2n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AURKA O14965 7/20 0.39
▸ HRH3 Q9Y5N1 1/20 0.34
▸ DDX3X O00571 1/20 0.33
▸ BCHE P06276 1/20 0.32
▸ ACHE P22303 1/20 0.32
▸ SLC40A1 Q9NP59 2/20 0.32
▸ AURKB Q96GD4 3/20 0.32
▸ NTRK1 P04629 1/20 0.32
▸ CSF1R P07333 1/20 0.32
▸ FLT3 P36888 1/20 0.32
▸ NTRK3 Q16288 1/20 0.32
▸ NTRK2 Q16620 1/20 0.32
▸ PPIA P62937 1/20 0.31
▸ FERMT2 Q96AC1 1/20 0.31
▸ PRKCA P17252 1/20 0.31
▸ PRKACB P22694 1/20 0.31
▸ FAAH O00519 1/20 0.31
▸ HTR2C P28335 1/20 0.31
▸ HTR2B P41595 1/20 0.31
▸ KDR P35968 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13430281 0.88 AURKA (0.49) AURKAAURKBNTRK1CSF1RFLT3
SCHEMBL13430277 0.85 AURKA (0.52) AURKAHRH3AURKBNTRK1CSF1R
SCHEMBL13430208 0.84 AURKA (0.37) AURKAAURKBNTRK1CSF1RFLT3
SCHEMBL13430286 0.79 AURKA (0.41) AURKAHRH3AURKBFAAHKDR
SCHEMBL13399883 0.79 AURKA (0.60) AURKAAURKBNTRK1CSF1RFLT3
SCHEMBL13430288 0.79 AURKA (0.39) AURKAHRH3ACHEAURKB
SCHEMBL13430283 0.77 AURKA (0.54) AURKAAURKBNTRK1CSF1RFLT3
SCHEMBL13430228 0.76 AURKA (0.69) AURKAAURKBNTRK1CSF1RFLT3
SCHEMBL13430229 0.74 AURKA (0.56) AURKAAURKBKDR
SCHEMBL13430207 0.74 AURKA (0.39) AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8765953-B2 Compounds and methods for the treatment of pain and other diseases AQUILUS PHARMACEUTICALS, INC. (US) 2014-07-01 — — US disclosed
WO-2010036629-A2 FUSED MULTICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2010-04-01 — — WO disclosed
Send feedback